NuCana plc (NCNA) NASDAQ

0.39

-0.0139(-3.44%)

Updated at May 07 09:34AM

Currency In USD

NuCana plc

Address

3 Lochside Way

Edinburgh, EH12 9DT

United Kingdom of Great Britain and Northern Ireland

Phone

44 13 1357 1111

Sector

Healthcare

Industry

Biotechnology

Employees

20

First IPO Date

September 28, 2017

Key Executives

NameTitlePayYear Born
Mr. Hugh Stephen GriffithFounder, Chief Executive Officer & Executive Director877,6301968
Mr. Martin Alexander QuinnCompany Secretary0N/A
Ms. Theresa BruceSenior Vice President of Clinical Operations0N/A
Mr. Gordon KennovinSenior Vice President of CMC & Development0N/A
Ms. Elisabeth OelmannSenior Vice President of Medical & Clinical Development0N/A
Mr. David HarrisonHead of Translational Medicine & Studies01960
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.Chief Medical Officer01958
Dr. Stuart GrantSenior Vice President of Regulatory Affairs0N/A

Description

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.